Insider · CIK 0001310880
David Hung
Files at NVCR (NovoCure Ltd), NUVB (Nuvation Bio Inc.). First filing Apr 8, 2025, latest Jun 3, 2026.
David Hung files SEC Form 4 as CEO, president, director and 10% owner at NVCR (NovoCure Ltd), and also at NUVB (Nuvation Bio Inc.). Since Apr 8, 2025, David Hung has reported 2 open-market buys worth $1.7M and 2 open-market sells worth $64k, the latest filed on Jun 3, 2026.
A track record needs three past buys with six months of prices behind them; David Hung has 2, so none is measured yet.
The newest scored trade: sold $46k of NVCR on Jun 2, 2026, filed Jun 3, 2026, scored 41 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $46k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
NUVB: Nuvation Bio Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | NovoCure Ltd | $46k 2,945 shares | -13% | +58% from low-14% from high | |
| 72Notable | Nuvation Bio Inc. | $894k 500,000 shares | +1% | +12% from low-43% from high | |
| 30Weak | NovoCure Ltd | $17k 999 shares | -8% | +17% from low-49% from high | |
| 68Notable | Nuvation Bio Inc. | $820k 500,000 shares | +1% | 0% from low-49% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,610 | $0.00 | $0 | 32,075 | Jun 5, 2026 |
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,999 | $0.00 | $0 | 16,999 | Jun 5, 2026 |
| Jun 2, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -2,945 | $15.77 | $46k | 20,465 | Jun 3, 2026 |
| Feb 27, 2026 | NUVB Nuvation Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,995,012 | $0.00 | $0 | 1,995,012 | Mar 3, 2026 |
| Jun 16, 2025 | NUVB Nuvation Bio Inc. | POpen-market purchase Class A Common Stock | +500,000 | $1.79 | $894k | 59,281,054 | Jun 18, 2025 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,215 | $0.00 | $0 | 23,410 | Jun 6, 2025 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,697 | $0.00 | $0 | 16,697 | Jun 6, 2025 |
| Jun 3, 2025 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -999 | $17.30 | $17k | 12,195 | Jun 4, 2025 |
| Apr 4, 2025 | NUVB Nuvation Bio Inc. | POpen-market purchase Class A Common Stock | +200,000 | $1.66 | $333k | 58,481,054 | Apr 8, 2025 |
| Apr 7, 2025 | NUVB Nuvation Bio Inc. | POpen-market purchase Class A Common Stock | +300,000 | $1.63 | $488k | 58,781,054 | Apr 8, 2025 |
| Feb 28, 2025 | NUVB Nuvation Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 4, 2025 |
Questions about David Hung
Answered from the filings on this page, as of the latest one.
Is David Hung buying or selling?
In the last 12 months David Hung reported 0 open-market buys worth $0 and 1 open-market sell worth $46k on SEC Form 4; the latest was sold $46k of NVCR on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did David Hung's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Hung has 2.
Where does David Hung file Form 4?
David Hung has filed Form 4 at NVCR (NovoCure Ltd); NUVB (Nuvation Bio Inc.) as PRESIDENT AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.